Appoints Christian Schade as Executive Chairman and Graeme Bell as Interim CEO

任命克里斯蒂安·沙德为执行主席，格雷姆·贝尔为临时首席执行官

BOSTON, Jan. 16, 2024 /PRNewswire/ -- Valo Health, Inc ('Valo'), a technology company focused on utilizing large scale data and artificial intelligence ('AI') driven computation to discover and develop therapeutics, today announced the appointment of Christian Schade as the newly-created role of Executive Chairman of the Board of Directors and Graeme Bell as interim CEO, effective immediately..

波士顿，2024年1月16日/PRNewswire/--Valo Health，Inc（“Valo”）是一家专注于利用大规模数据和人工智能（“AI”）驱动的计算来发现和开发治疗方法的技术公司，今天宣布任命克里斯蒂安·沙德（Christian Schade）为董事会执行主席，格雷姆·贝尔（Graeme Bell）为临时首席执行官，立即生效。。

Schade has served as a Board Director for Valo Health since September 2023, a role he took on after joining Flagship Pioneering as Growth Partner in January 2023. Bell has served as Executive Vice President and Chief Financial Officer for Valo since 2020, and has assumed numerous operational responsibilities during his time with the company, including as Chief People Officer.

自2023年9月以来，Schade一直担任Valo Health的董事会董事，这是他在2023年1月加入Flagship Expandative成为增长合作伙伴后担任的一个职位。自2020年以来，贝尔一直担任Valo的执行副总裁兼首席财务官，并在公司任职期间承担了多项运营职责，包括担任首席人事官。

Bell succeeds David Berry, M.D., Ph. D., who has served as CEO of Valo Health since its launch by Flagship Pioneering in 2019 and whose last day of employment is February 2..

Bell接替DavidBerry，M.D.，Ph.D.，自2019年Flagship Advantigination推出Valo Health以来，他一直担任首席执行官，就职的最后一天是2月2日。。

'Chris and Graeme have made tremendous contributions to Valo during their tenure, and the Board of Directors is confident they are the right leaders for Valo's future,' said Paul Biondi, Chairman of the Board of Directors, Valo Health, and Executive Partner, Flagship Pioneering. 'I look forward to working with Chris, Graeme and the entire leadership team to continue Valo's mission to use large scale human-centric data to develop better therapeutics faster.'.

Valo Health董事会主席兼旗舰先锋执行合伙人保罗·比昂迪（PaulBiondi）说：“克里斯（Chris）和格雷姆（Graeme）在任期内为Valo做出了巨大贡献，董事会相信他们是Valo未来的正确领导者。”我期待着与Chris、Graeme和整个领导团队合作，继续Valo的使命，利用大规模以人为中心的数据更快地开发更好的治疗方法。”。

'In addition to his tenure as CFO, Graeme has become integral to the operations of Valo, making him the ideal person to lead the company as CEO,' added Schade. 'I look forward to continuing to partner with Graeme, the Board of Directors, and Valo's team to progress our vision of transforming the drug discovery and development process using proprietary and differentiated human-centric data and AI-driven computation for the ultimate benefit of patients.'.

“除了担任首席财务官之外，格雷姆已经成为瓦洛运营不可或缺的一员，这使他成为领导公司担任首席执行官的理想人选，”沙德补充道我期待着继续与Graeme、董事会和Valo的团队合作，推进我们的愿景，即使用专有和差异化的以人为中心的数据和人工智能驱动的计算来改变药物发现和开发过程，为患者带来最终利益。”。

'The tremendously talented team at Valo and the organization's deep commitment to our mission have inspired me since joining the company,' added Bell. 'I look forward to taking the company forward, realizing the potential of Opal, our computational platform, to speed up drug discovery and development both within Valo and with our partners.'.

贝尔补充道：“自从加入公司以来，瓦洛极具天赋的团队和该组织对我们使命的坚定承诺激励了我。”我期待着带领公司前进，实现我们的计算平台Opal的潜力，以加速Valo内部和我们的合作伙伴的药物发现和开发。”。

About Christian S. Schade

关于Christian S.Schade

Christian S. Schade has more than 30 years of private and public pharmaceutical and biotechnology industry experience, as well as broad corporate finance expertise from his tenure in investment banking. Prior to Flagship, he served as the Chairman and CEO of Aprea Therapeutics Inc., a clinical-stage biopharmaceutical company.

克里斯蒂安·沙德（Christian S.Schade）在私人和公共制药和生物技术行业拥有30多年的经验，在投资银行任职期间拥有广泛的企业融资专业知识。在加入Flagship之前，他曾担任临床阶段生物制药公司Aprea Therapeutics Inc.的董事长兼首席执行官。

Prior to Aprea, Schade's previous roles include CEO of Novira (acquired by Johnson & Johnson), Executive Vice President (EVP) and Chief Financial Officer (CFO) of Omthera Pharmaceuticals, Inc. (acquired by AstraZeneca Plc), EVP and CFO at NRG Energy Inc., and Senior Vice President of Administration and CFO at Medarex, Inc.

在加入Aprea之前，Schade曾担任Novira首席执行官（被强生收购）、Omthera Pharmaceuticals，Inc.（被阿斯利康收购）执行副总裁（EVP）和首席财务官（CFO）、NRG Energy Inc.执行副总裁和首席财务官，以及Medarex，Inc.行政副总裁和首席财务官。

(acquired by Bristol Myers Squibb). Before Medarex, Schade served as Managing Director at Merrill Lynch in London and held various corporate finance and capital markets positions in New York and London for both Merrill Lynch and JP Morgan Chase & Co. Schade currently serves as Chair of the Board of Directors of Omega Therapeutics, Inc., Alltrna Therapeutics and serves on the Boards of Ring Therapeutics, and Integra LifeSciences Inc., where he chairs the Audit and Finance Committees..

（由百时美施贵宝收购）。在Medarex之前，Schade曾担任美林（Merrill Lynch）驻伦敦董事总经理，并在纽约和伦敦为美林（Merrill Lynch）和摩根大通（JP Morgan Chase＆Co.）担任多个公司财务和资本市场职位。Schade目前担任欧米茄治疗公司（Omega Therapeutics，Inc.）、Alltrna治疗公司（Alltrna Therapeutics）董事会主席，并担任Ring Therapeutics董事会成员，以及Integra LifeSciences Inc.，他担任审计和财务委员会主席。。

About Graeme Bell

关于格雷姆·贝尔

Graeme Bell has served as Valo's Chief Financial Officer since August 2020 and, since October 2022, Valo's Chief People Officer. He has a distinguished 30-year career as a financial executive in the biopharmaceutical sector with a broad range of experience successfully driving strategic financial operations.  Previously, Bell was Chief Financial Officer at Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company in Philadelphia, Pennsylvania from September 2018 to June 2020.

格雷姆·贝尔自2020年8月起担任瓦洛的首席财务官，自2022年10月起担任瓦洛的首席人事官。作为生物制药行业的财务主管，他拥有30年的杰出职业生涯，拥有成功推动战略性财务运营的广泛经验。此前，贝尔曾于2018年9月至2020年6月担任位于宾夕法尼亚州费城的私营临床阶段生物治疗公司Tmunity Therapeutics，Inc.的首席财务官。

Prior to Tmunity, Bell served as Chief Financial Officer of Intellia Therapeutics, Inc. from December 2016 to August 2018. Bell was also Chief Financial Officer and Chief People Officer at Anacor Pharmaceuticals, Inc. from June 2015 to November 2016. From 1993 until May 2015, Bell served in a number of positions of increasing responsibility at Merck & Co., Inc., including Country Chief Financial Officer, U.S.

在加入Tmunity之前，贝尔于2016年12月至2018年8月担任Intellia Therapeutics，Inc.的首席财务官。2015年6月至2016年11月，贝尔还担任Anacor Pharmaceuticals，Inc.的首席财务官和首席人事官。从1993年到2015年5月，贝尔在默克公司（Merck＆Co.，Inc.）担任了多个职责越来越重的职位，包括美国国家首席财务官。

Human Health from 2010 to May 2015, Global Pharmaceutical Franchises Controller from October 2009 to July 2010, Country Chief Financial Officer, U.K. from 2008 to 2009, and Global Head of Investor Relations from August 2002 to July 2008. Bell holds an M.B.A. from Durham University, England and is a Fellow of the Chartered Institute of Management Accountants (CIMA)..

2010年至2015年5月的人类健康，2009年10月至2010年7月的全球制药特许经营总监，2008年至2009年的英国国家首席财务官，以及2002年8月至2008年7月的全球投资者关系总监。贝尔拥有英国达勒姆大学的工商管理硕士学位，是英国特许管理会计师协会（CIMA）的会员。。

About Valo HealthValo Health, Inc is a technology company focused on utilizing large scale data and AI-driven computation to discover and develop therapeutics. Valo aims to fully integrate human-centric data across the entire drug development life cycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing costs, time, and failure rates.

关于Valo Health Valo Health，Inc是一家技术公司，专注于利用大规模数据和AI驱动的计算来发现和开发治疗方法。Valo旨在将整个药物开发生命周期中以人为中心的数据完全整合到一个统一的体系结构中，从而加速发现和开发改变生命的药物，同时降低成本，时间和失败率。

The company's Opal Computational Platform™ is an end-to-end drug discovery and development platform with a unified architecture designed to transform data into valuable insights that may accelerate discoveries and enable Valo to advance a robust pipeline of programs, initially focused on cardiovascular metabolic renal, oncology, and neurodegenerative disease.

该公司的蛋白石计算平台™ 是一个端到端的药物发现和开发平台，具有统一的体系结构，旨在将数据转化为有价值的见解，从而加速发现，并使Valo能够推进强大的程序管道，最初专注于心血管代谢性肾脏病，肿瘤学和神经退行性疾病。

Founded by Flagship Pioneering and headquartered in Boston, MA, Valo also has offices in Lexington, MA, and New York, NY. To learn more, visit valohealth.com..

Valo由Flagship Expediantive创立，总部位于马萨诸塞州波士顿，在马萨诸塞州列克星敦和纽约州纽约也设有办事处。要了解更多信息，请访问valohealth.com。。

ContactsInvestors: Graeme Bell, [email protected] Media: Kate Clayton, [email protected]

联系人投资者：格雷姆·贝尔，[电子邮件保护]媒体：凯特·克莱顿，[电子邮件保护]

SOURCE Valo Health, Inc.

来源Valo Health，Inc。